Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (2)

2024

  1. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

2023

  1. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068